877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Pyrazoles, Psychoactive drug

Categories

Cyclic compounds (5)
Drugs acting on the nervous system (5)
Five-membered rings (5)
Psychoactive drugs (5)
Analgesics (3)
Six-membered rings (3)
Aromatic compounds (2)
Cannabinoids (2)
Cannabis (2)
Chloroarenes (2)
Monoamine reuptake inhibitors (2)
Opioid antagonists (2)
Opioid receptor ligands (2)
Opioids (2)
Piperidines (2)
Pyrazolecarboxamides (2)
AM cannabinoids (1)
Amines (1)
Analgesic (1)
Anorectics (1)
Anti-inflammatory agents (1)
Anti-inflammatory and antirheumatic products (1)
Antidepressants (1)
Antiobesity drugs (1)
Antipyretics (1)
Anxiogenics (1)
Anxiolytics (1)
Bases (chemistry) (1)
Cannabinoid (1)
Dopamine reuptake inhibitors (1)
Drugs acting on the gastrointestinal system and metabolism (1)
Drugs acting on the musculoskeletal system (1)
Iodoarenes (1)
Monoamine oxidase inhibitors (1)
Nervous system drug (1)
Nonsteroidal anti-inflammatory drugs (1)
Pharmaceuticals (1)
Piperazines (1)
Psychopharmacology (1)
Serotonin-norepinephrine reuptake inhibitors (1)

Suppliers

Matrix Scientific (1)
Sigma Aldrich (1)

Rimonabant (168273-06-1, 158681-13-1)  
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) was an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class.
AM251 (183232-66-8)  
AM 251  ·  N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide  ·  N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
AM-251 is an inverse agonist at the CB1 cannabinoid receptor. AM-251 is structurally very close to SR141716A (rimonabant); both are biarylpyrazole cannabinoid receptor antagonists. In AM-251 the p-chloro group attached to the phenyl substituent at C-5 of the pyrazole ring is replaced with a p-iodo group.
Difenamizole (20170-20-1, 20170-21-2)  
Difenamizole (INN) (brand name Pasalin; former developmental code name AP-14) is a nonsteroidal anti-inflammatory drug (NSAID) and analgesic of the pyrazolone group related to metamizole. It has monoaminergic properties, including inhibition of monoamine oxidase, augmentation of pargyline-induced elevation of striatal dopamine levels, inhibition of K+-induced striatal dopamine release, and inhibition of the reuptake of dopamine.
Fezolamine (80410-36-2)  
Fezolamine (Win-41,528-2) is a drug which was investigated by Sterling Drug as an antidepressant in the 1980s. The isomeric N,N-dimethyl-4,5-diphenyl-1H-pyrazole-1-propanamine was completely inactive in the primary antidepressant screens. It acts as a serotonin, norepinephrine, and dopamine reuptake inhibitor, with 3- to 4-fold preference for the former neurotransmitter.
Enpiprazole (31729-24-5)  
Enpiprazole (INN, BAN) is an anxiolytic drug of the phenylpiperazine group that was never marketed. It produces anxiolytic-like effects in animals, though these effects appear to be biphasic and may reverse at high doses. It is known to produce ortho-chlorophenylpiperazine (oCPP) as a metabolite.
Related searches
Pyrazoles
Psychoactive drug